Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers

V. D. Ivaturi, J. R. Riss, R. L. Kriel, J. C. Cloyd

Research output: Contribution to journalComment/debate

21 Scopus citations

Abstract

Objective - The purpose of this pilot study was to determine the pharmacokinetics and tolerability of an investigational diazepam (DZP) formulation and a parenteral midazolam (MDZ) formulation following intranasal (i.n.) administration for the efficient treatment of seizure emergencies. Methods - Each subject received 5 mg of DZP and MDZ via both i.n. and intravenous routes in a four-way, randomized crossover trial. Blood samples were collected over 48 h. DZP and MDZ concentrations were measured using HPLC. Using analog scales, subjects rated tolerability (0 = no change from normal; 10 = maximum intolerability) and pain (0 = no pain; 4 = extreme pain) prior to and 0, 5, 15, 60 min, and 8 h after administration. Results - The Cmax and Tmax values for i.n. DZP and MDZ were 179.2 ng/ml and 28.8 min vs 62.8 ng/ml and 21.6 min, respectively. Immediately following i.n. administration, subjects reported tolerability scores of 6.75 and 6.0, and identical pain scores, 3.2, for DZP and MDZ, respectively. Conclusion - Both formulations were rapidly absorbed following i.n. administration with transient discomfort. DZP had a longer half-life, which may result in an extended duration of action. Further studies in large patient populations to evaluate the safety after long term use, efficacy and pharmacokinetics of i.n. DZP are warranted.

Original languageEnglish (US)
Pages (from-to)353-357
Number of pages5
JournalActa Neurologica Scandinavica
Volume120
Issue number5
DOIs
StatePublished - Nov 1 2009

Keywords

  • Diazepam
  • Intranasal
  • Midazolam
  • Pharmacokinetics
  • Tolerability

Fingerprint Dive into the research topics of 'Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers'. Together they form a unique fingerprint.

  • Cite this